Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$26.65 USD
+0.58 (2.22%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $26.64 -0.01 (-0.04%) 6:04 PM ET
3-Hold of 5 3
A Value D Growth D Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PCRX 26.65 +0.58(2.22%)
Will PCRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PCRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PCRX
Here's What Key Metrics Tell Us About Pacira (PCRX) Q2 Earnings
Pacira (PCRX) Tops Q2 Earnings Estimates
PCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is the Options Market Predicting a Spike in Pacira BioSciences Stock?
Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates
Pacira (PCRX) Reports Q1 Earnings: What Key Metrics Have to Say
Other News for PCRX
Fell Below 20 Day Moving Average appears for PCRX after 1.66% move
NR7 appears for PCRX after 1.3% move
20 Day Moving Average Support appears for PCRX after 0.96% move
The technical outlook for PCRX is unchanged after it rises 0.33% on September 12
PCRX forms 20 Day Moving Average Support on September 11